Cover

Recent Advances in Tonsils and Mucosal Barriers of the Upper Airways

7th International Symposium on Tonsils and Mucosal Barriers of the Upper Airways, Asahikawa, July 2010: Proceedings

Editor(s): Harabuchi Y. (Asahikawa) 
Hayashi T. (Asahikawa) 
Katada A. (Asahikawa) 
Table of Contents
Vol. 72, 2011
Section title: Innate Immunology
Harabuchi Y (ed): Recent Advances in Tonsils and Mucosal Barriers of the Upper Airways. Adv Otorhinolaryngol. Basel, Karger, 2011, vol 72, pp 93–96
(DOI:10.1159/000324622)

Role of Biofilms in Chronic Inflammatory Diseases of the Upper Airways

Calò L. · Passàli G.C. · Galli J. · Fadda G. · Paludetti G.
Institutes of aOtorhinolaringology and b Microbiology, Catholic University of the Sacred Heart, Rome, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The objective of our studies was to document the presence of bacterial biofilms in recurrent and chronic infectious diseases of the upper airways (UA) (adenoiditis, tonsillitis, chronic rhinosinusitis) and to assess the association between the presence of biofilm and the maintenance of a chronic inflammation. Methods: 16 surgical samples of tonsils and adenoids from patients with UA infections and 24 samples of ethmoid mucosa from patients who underwent endoscopic sinus surgery for chronic rhinosinusitis (CRS) were cultured using conventional methods and subjected to scanning electron microscopy (SEM) to detect evidence of biofilm. Results: Bacterial biofilms were observed in 57.5% of chronically infected UA mucosa; in 41.7% of ethmoid mucosa of CRS patients they were significantly (p < 0.001) associated with a marked destruction of ciliated epithelium. Discussion: Our studies confirm that biofilm formation plays a role in UA infections, it not only explains the resistance of these infections to antibiotic therapy, but also represents an important element that contributes to the maintenance of a chronic inflammatory reaction.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilm: a common cause of persistent infections. Science 1999;284:1318-1322
  2. Hall-Stoodley L, Hu FZ, Gieseke A, et al: Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006;296:202-211
  3. Flemming HC, Wingender J: The biofilm matrix. Nat Rev Microbiol 2010;8:623-633
  4. Galli J, Calò L, Ardito F, Imperiali M, Bassotti E, Fadda G, Paludetti G: Biofilm formation by Haemophilus influenzae isolated from adeno-tonsil tissue samples, and its role in recurrent adenotonsillitis. Acta Otorhinolaryngol Ital 2007;27:134-138
  5. Saylam G, Tatar EC, Tatar I, Ozdek A, Korkmaz H: Association of adenoid surface biofilm formation and chronic otitis media with effusion. Arch Otolaryngol Head Neck Surg 2010;136:550-555
  6. Winther B, Gross BC, Hendley JO, Early SV: Location of bacterial biofilm in the mucus overlying the adenoid by light microscopy. Arch Otolaryngol Head Neck Surg 2009;135:1239-1245
  7. Palmer J: Bacterial biofilms in chronic rhinosinusitis. Ann Otol Rhinol Laryngol (suppl)2006;196:35-39
  8. Bendouah Z, Barbeau J, Hamad WA, Desrosiers M: Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis. Otolaryngol Head Neck Surg 2006;134:991-994
  9. Galli J, Calò L, Ardito F, Imperiali M, Bassotti E, Passàli GC, La Torre G, Paludetti G, Fadda G: Damage to ciliated epithelium in chronic rhinosinusitis: what is the role of bacterial biofilms?. Ann Otol Rhinol Laryngol 2008;117:902-908
  10. Galli J, Ardito F, Calò L, Mancinelli L, Imperiali M, Parrilla C, Picciotti PM, Fadda G: Recurrent upper airway infections and bacterial biofilms. J Laryngol Otol 2007;121:341-344


Pay-per-View Options
Direct payment This item at the regular price: USD 28.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 19.50